Guangdong Baiyi Pharmaceutical

Guangdong Baiyi Pharmaceutical is a leading Chinese pharmaceutical company focused on the distribution and commercialization of plasma-derived therapies. Based in Guangzhou, the company provides a comprehensive range of blood products, including human albumin, intravenous immunoglobulins, and coagulation factors, to hospitals and healthcare centers across China. In 2023, the company was fully acquired by China Resources Boya Bio-pharmaceutical, a move that integrated its extensive sales network into the broader China Resources Group. Guangdong Baiyi plays a vital role in the domestic biopharmaceutical market by ensuring the efficient supply of critical care and immunology treatments. Its operations are characterized by a strong emphasis on cold-chain logistics and regulatory compliance in the blood products sector.